Get started
Altimmune, Inc.Altimmune, Inc.Altimmune, Inc.

Altimmune, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ALT chart


Full chart

Key facts today

Altimmune's shares increased by 2.2% in premarket trading after Novo Nordisk's obesity drug showed underperformance in a late-stage trial.
Analyze the impactAnalyze the impact

ALT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪581.80 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.55 USD
Net income (FY)
‪−88.45 M‬ USD
Revenue (FY)
‪426.00 K‬ USD
Shares float
‪70.53 M‬
Beta (1Y)
3.12

Employees


Employees (FY)
59
Change (1Y)
+7 +13.46%
Revenue / Employee (1Y)
‪7.22 K‬ USD
Net income / Employee (1Y)
‪−1.50 M‬ USD

About Altimmune, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Vipin K. Garg
Website
altimmune.com
Headquarters
Gaithersburg
Founded
1997
FIGI
BBG000FXML90
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ALT is 8.25 USD — it has increased by 0.86% in the past 24 hours. Watch Altimmune, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Altimmune, Inc. stocks are traded under the ticker ALT.
ALT stock has fallen by −4.51% compared to the previous week, the month change is a 8.41% rise, over the last year Altimmune, Inc. has showed a 0.12% increase.
We've gathered analysts' opinions on Altimmune, Inc. future price: according to them, ALT price has a max estimate of 28.00 USD and a min estimate of 12.00 USD. Watch ALT chart and read a more detailed Altimmune, Inc. stock forecast: see what analysts think of Altimmune, Inc. and suggest that you do with its stocks.
ALT reached its all-time high on Mar 14, 2006 with the price of 2,724.00 USD, and its all-time low was 1.51 USD and was reached on Nov 19, 2019. View more price dynamics on ALT chart.
See other stocks reaching their highest and lowest prices.
ALT stock is 6.97% volatile and has beta coefficient of 3.12. Track Altimmune, Inc. stock price on the chart and check out the list of the most volatile stocks — is Altimmune, Inc. there?
Today Altimmune, Inc. has the market capitalization of ‪586.78 M‬, it has decreased by −3.89% over the last week.
Yes, you can track Altimmune, Inc. financials in yearly and quarterly reports right on TradingView.
Altimmune, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ALT earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.36 USD resulting in a 10.26% surprise. The estimated earnings for the next quarter are −0.34 USD per share. See more details about Altimmune, Inc. earnings.
Altimmune, Inc. revenue for the last quarter amounts to ‪5.00 K‬ USD, despite the estimated figure of 714.00 USD. In the next quarter, revenue is expected to reach 0.00 USD.
ALT net income for the last quarter is ‪−22.84 M‬ USD, while the quarter before that showed ‪−24.64 M‬ USD of net income which accounts for 7.28% change. Track more Altimmune, Inc. financial stats to get the full picture.
No, ALT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 59.00 employees. See our rating of the largest employees — is Altimmune, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Altimmune, Inc. EBITDA is ‪−97.42 M‬ USD, and current EBITDA margin is ‪−19.49 K‬%. See more stats in Altimmune, Inc. financial statements.
Like other stocks, ALT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Altimmune, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Altimmune, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Altimmune, Inc. stock shows the sell signal. See more of Altimmune, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.